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Abstract.  Scatter factor (SF) (also known as hepato- 
cyte growth factor [HGF]) is a fibroblast-derived 
cytokine that stimulates motility, proliferation,  and 
morphogenesis of epithelia.  SF may play major roles 
in development, repair,  and carcinogenesis.  However, 
the physiologic signals that regulate its production are 
not well delineated.  We found that various human tu- 
mor cell lines that do not produce SF secrete factors 
that stimulate SF production by fibroblasts, suggesting 
a paracrine mechanism for regulation of SF produc- 
tion.  Conditioned medium from these cell lines con- 
tained two distinct scatter factor-inducing factor SF-IF 
activities:  a high molecular weight (>30 kD), heat 
sensitive activity and a low molecular weight (<30 
kD) heat stable activity. Further studies revealed that 
SF-producing fibroblasts also secrete factors that 
stimulate their own SF production.  We characterized 
the <30-kD SF-IF activity from ras-3T3 (clone D4), a 
mouse cell line that overproduces both SF and SF-IE 
The <30-kD filtrate from ras-3T3 conditioned medium 
induced four- to sixfold increases in expression of SF 
biologic activity, immunoreactive protein,  and mRNA 
by multiple SF-producing fibroblast lines. Ras-3T3 SF- 
IF activity was stable to boiling, extremes of pH, and 
reductive alkylation,  but was destroyed by proteases. 
We purified ras-3T3 SF-IF about 10,000-fold from 
serum-free conditioned medium by a combination of 
ultrafiltration,  cation exchange chromatography,  and 
reverse phase chromatography.  The purified protein 
exhibited electrophoretic mobility of about 12 kD (re- 
duced) and  14 kD (nonreduced) by SDS-PAGE. The 
identity of the protein was verified by elution of bio- 
logic activity from gel slices. Purified SF-IF stimu- 
lated SF production in a physiologic concentration 
range (about 20--400 pM).  Its properties and activities 
were distinct from those of IL-1  and TNF, two known 
inducers of SF production.  We suggest that SF-IF is a 
physiologic regulator of SF production. 
S 
CATTER factor (SF) ~ was characterized  as a cytokine 
secreted by stromal cell types that causes normally co- 
hesive colonies of epithelial  cells to spread out and to 
separate into individual  cells (Stoker and Perryman,  1985; 
Stoker et al.,  1987; Rosen et al.,  1989).  SF is now known 
to be identical to hepatocyte growth factor (HGF) (Weidner 
et al.,  1991; Bhargava et al.,  1992; Furlong et al.,  1991), a 
serum-derived mitogen for mature rat hepatocytes (Miya- 
zawa et al.,  1989;  Nakamura et al.,  1989;  Zarnegar  and 
Michalopoulos, 1989). SF is a basic heparin-binding  glyco- 
protein consisting  of a heavy (60 kD) and a light  (30 kD) 
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1. Abbreviations  used in this paper: CM, Conditioned medium; ECL, en- 
hanced chemiluminescence; HGF, hepatocyte growth factor; RPC, reverse 
phase chromatography; SF, scatter factor; SF-IF, SF-inducing factor; TFA, 
trifluoroacetic acid. 
chain  (Gherardi  et ai.,  1989;  Rosen et al.,  1989, 1990a; 
Weidner et al.,  1990; Rubin et al.,  1991). SF is a member 
of the family of kringle  proteins.  It exhibits similar  subunit 
structure  and  38%  amino  acid  sequence identity  to  the 
proenzyme plasminogen  (Nakamura et al., 1989). However, 
SF lacks proteolytic activity due to two critical  amino acid 
substitutions at the catalytic center of its light chain. The cell 
surface receptor for SF was identified as the protein product 
of the c-met proto-oncogene, a 190-kD transmembrane tyro- 
sine kinase (Bottaro et al.,  1991; Naldini  et al.,  1991). 
Recent studies  suggest that SF may play significant  roles 
in embryogenesis (Sonnenberg et al., 1993); morphogenesis 
of epithelia  tissue (Montesano et al.,  1991; Tsarfaty et ai., 
1992); blood vessel formation (Bussolino et al,, 1992; Grant 
et al.,  1993);  organ  regeneration  (Matsumoto and Naka- 
mura,  1993; Tsubouchi  et al.,  1993);  and tumor cell dis- 
semination (Weidner et al., 1990; Rosen et al., 1990b, 1991, 
1994). Although  some epithelial  cell lines produce modest 
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primary mode of action is thought to be paracrine.  The ma- 
jor producer  cell  types  (e.g.,  fibroblasts,  smooth  muscle 
cells,  macrophages)  are  distinct  from  the  responder  cell 
types (epithelium, endothelium, melanocytes) (Stoker et al., 
1987; Rosen et al., 1989,  1990a; Rubin et al.,  1991). To fur- 
ther understand how SF functions in vivo, we have studied 
the factors that regulate its synthesis and secretion. We now 
report that SF production by fibroblasts and other stromal 
cell types is regulated,  in part, by autocrine and paracrine 
mechanisms  involving the accumulation  of soluble scatter 
factor-inducing factors (SF-IFs). We characterized one such 
factor from an immortal  fibroblast line that overproduces 
both SF and SF-IE 
Materials and Methods 
Cell 7)jpes and Sources 
Ras-transformed NIH/2-3T3  mouse fibroblasts (clone IM) (Stoker et al., 
1987) were obtained from Dr. M. Stoker. MDCK cells were obtained from 
Dr. S. Warren (Yale University School of Medicine, New Haven, CT). Hu- 
man fibroblast (CCDllLu, WI38, CCD32Lu, CCL33Lu, MRC5, CCL215, 
3ASubE), mouse fibroblast (BALB/c-3T3,  Swiss albino 3T3),  human squa- 
mous carcinoma (A253,  Calul),  human glioblastoma (Ug7MG, Hs683), 
and  human  mammary  carcinoma  (SKBr3,  MCF'/,  BT549,  MDA23, 
MDA468,  Hs578T,  T47D)  cell lines were purchased from the American 
Type  Culture  Collection  (RockviUe,  MD).  Human  mammary  tumor- 
derived fibroblasts (l136TF)  were provided by Dr.  H.  Smith (Geraldine 
Brush Cancer Research Institute, San Francisco, CA). Early passage human 
mammary tumor cell strains (173T, 186TL) were provided by Dr. P. Stamp- 
fer (Lawrence Berkeley Laboratory,  University of California,  Berkeley, 
CA). Human ovary carcinoma (YaOvBix2NMA, SKOV3, HEY) and mouse 
macrophage (Bac2FS) cell lines were provided by Dr. B. Kacinski (Yale 
University School of Medicine). Human melanoma cell lines (WW943, 
MeWo, Zazzaro) were provided by Dr. R. Haiaban (Yale University School 
of Medicine).  C2  rat  bepatoma cells were provided by  Dr.  M.  Weiss 
(Pasteur Institute,  Paris,  France).  Bovine pericyte conditioned medium 
(CM) was provided by Dr. P. D~maore (Children's Hospital Medical Center, 
Boston, MA). Human macrophage CM was provided by Dr. O. Einnarson 
(Yale University School of Medicine). 
Cell Culture 
Cells were grown in DME plus 10% (vol/vol) fetal calf serum (5% for ras- 
3T3 cells), 0.1 mM nonessential amino acids, penicillin (100  U/ml), and 
streptomycin (100/zg/mi), as described earlier (Rosen et al., 1990a), with 
the following exceptions. Bac2F5 cells were grown in Iscove's medium sup- 
plemented with  10%  fetal calf serum and  100  ng/mi colony stimulating 
factor-I (CSF-1); and 1731" and 186TL breast carcinoma cells were cultured 
in a defined medium based on MCDB 170, as described before (Stampfer 
ct al., 1980).  Cells were subeultured at weekly intervals using trypsin; re- 
seeded at 1:4 (human lung fibroblasts, lI36TF) or 1:10 (all other cell types); 
and incubated at 37°C in a humidified atmosphere of 5% CO2 and 95% 
air.  Fibroblasts were studied within two to four passages after thawing of 
ampules. 
Assay of  CM  for SF-inducing  Activity 
To generate CM, confluent cultures of cells were washed three times and 
incubated in serum-free DME (0.1 mi/cm  2) for 48 h. The medium was cen- 
trifuged to remove debris and stored at -20°C. The ability of the CM to 
stimulate SF production by MRC5 or CCDI1Lu fibroblasts was assessed, 
as follows. Confluent fibroblasts in 2-cm  2 culture wells were washed and 
incubated in 0.5 ml of DME containing various dilutions of CM for 48 h. 
The resulting media were collected for SF assay, and the cells were counted 
using a Coulter counter. SF was quantitated by bioassay or ELISA. The SF 
production rate was expressed as MDCK scatter units or ng of SF/106 
cells/48 h. For each assay condition, two to four replicate determinations 
of SF and cell number were made. Each experiment was performed at least 
three times. 
Scatter Factor Bioassay 
SF activity was quantitated using the MDCK serial dilution scatter assay, 
as described before (Rosen et al.,  1989,  1990a).  The SF concentration at 
the limiting dilution was defined as 0.5 MDCK scatter U/ml, allowing calcu- 
lation of the SF titer in the original sample. 
Scatter Factor ELISA 
Immulon II 96-well plates (Dynatech Laboratories, Alexandria, VA) were 
coated with anti-human SF mouse monoclonal 23C2 ascites (Bhargava  et 
al., 1992) (1:1,000) in 0.1 M Na2CO3 buffer, pH 9.6, overnight at 4°C (100 
/~l/well).  Wells were washed four times with tris-buffered saline (20 mM 
tris, 150 mM NaC1, 0.05%  Tween-20, pH 7.5) (TBS), blocked with 0.5% 
gelatin in TBS for 1 h at 37°C; washed four times, incubated for I h at 37°C 
with 100/~l of test sample or standard (recombinant human SF; Genentech, 
Inc., San Francisco, CA), and re-washed. Wells were then incubated with 
rabbit anti-SF antiserum (Grant et al.,  1993) (1:2,000)  for 1 h at 37°C in 
0.25% gelatin in TBS, washed four times, incubated with goat anti-rabbit 
IgG conjugated to alkaline phosphatase (50  /~g/ml)  (1  h  at  37°C),  and 
washed again. Color was developed by incubation with 100/zl of substrate 
solution (p-nitro phenyl phosphate [1 mg/mi], 1 M diethanolamine HCI, 2 
mM MgC12, pH 9.8).  The reaction was stopped by adding 50/~1  of 3 M 
NaOH, and absorbance was read at 410 nm using a Dynatech 96-well spec- 
trophotometer. The assay was specific for SF. It did not detect plasminogen, 
albumin, or various other growth factors and cytokines. The standard curve 
was linear from 0.2-4.0 ng/mi of SF (useful measuring range). 
Northern Blotting 
Confluent fibroblasts in 100 mm dishes (10 ml DME/dish) were exposed 
to various treatments, and total cell RNA was isolated by acid guanidinium 
isothiocyanate-phenol-chloroform extraction  (Chomczynski and  Sacchi, 
1987).  Aliquots of RNA (20/zg/lane) were electrophoresed through 1% 
agarose-17%  formaldehyde gels, and RNA quality and loading were as- 
sessed by ethidium bromide staining. Northern transfers and hybridization 
were performed as described before (Elias and Lentz, 1990).  Membranes 
were probed with a  2.2-kb insert containing the complete human HFG 
eDNA subcloned into the Sail restriction site of  the pUC vector. (The insert 
was subcloned from the EMC-hHGF construct [Nakamura ct al.,  1989], 
provided by Dr. T. Nakamura). This probe will detect all SF mRNA tran- 
scripts, including the major 6-kb mRNA, the 3-kb mRNA (which also en- 
codes full-length protein), the 1.5-kb RNA (which encodes a truncated form 
of SF), and other mRNAs (four 2.2 kb) that have not been fully character- 
ized (Rubin et al.,  1991; Chen et al.,  1991). Sizes of transcripts were as- 
sessed by comparison to RNA size standards (Bio-Rad Laboratories, Rich- 
mond, VA).  A  eDNA encoding the 285 ribosomal gene (Erikson ct al., 
1981) was used as a control probe. (The 285 eDNA was provided by Dr. 
S.  Adams, University of Pennsylvania, Philadelphia, PA).  eDNA probes 
were labeled by nick translation to specific activities of '~109 CPM/t~g 
DNA. Membranes were washed with 0.5x  SSC containing 0.1% SDS for 
30 rain at 50°C, and autoradiography was performed. Densitometry was 
carried out using a Hoeffer GS370 densitometer, and data were analyzed 
using the GS300 software package. 
Western Blotting 
CM  samples were concentrated 20-fold by ultrafiltration  using  YM-30 
membrane (Amicon Corp., Danvers, MA). Aliquots (75 #1) were electro- 
phoresed under nonreducing conditions and blotted, using rabbit anti-SF 
antiserum (1:2,000)  as the primary antibody, as described before (Bhargava 
et al., 1992). Bound anti-SF antibody was detected by enhanced chemilumi- 
nescence (ECL) (Amersham Corp., Arlington Heights, IL). 
Interleukin-1 Preparations and IL  4 Bioassay 
Recombinant human intedeukin-1 (IL-1) a  and IL4/3 were a gift from Dr. 
R. Drummond (Cetus Corporation, Emeryville, CA). Recombinant murine 
IL-lt~ was a gift from Dr. E  Lomedico (Hoffman-La Roche). The levels of 
IL-1 in CM were quantitated using a sensitive and specific assay, based on 
the ability of IL-1 in the samples to stimulate proliferation of D10.N(4)M 
cells, a subelone of the IL-l-dependent cloned murine T cell line DI0.G4.1 
(Hopkins and Humphreys, 1989). The assay detected >/0.8 ng/ml of recom- 
binant mouse IL-lt~. 
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from Human Breast Carcinoma  Cells 
Cm tested*  MRC5  SF production 
(ng/lO  6 cells~24 h)* 
Control (0)  4 
SKBr3  10 
MCF7  9 
BT549  19 
MDA23  25 
MDA468  26 
Hs578T  6 
T47D  14 
173T  11 
186TL  13 
$ras-3T3  (D4)  24 
* Confluent  tumor cells were incubated  in DME (0.1  ml/cm  2)  for 48  h  to 
produce CM.  To assay  the CM for SF-inducing  activity,  confluent  MRC5 
fibroblasts in 2-cm  2 wells were incubated in 0.5 ml DME containing 50% CM 
for 24 h. The media were assayed for SF by ELISA. Values are means of two 
assays (range of + 15%). 
$ For ras-3T3 cells, which produce SF, the <30-kD filtrate of the CM was 
tested. 
Purification of ras-3T3 SF-IF 
SF-IF was purified from CM from ras-3T3  (D4), a  mouse cell line that 
produces very high titers of SF (Stoker et al., 1987; Rosen et al., 1990a). 
Cells were grown to confluency in Falcon 1750-cm  2 plastic roller bottles 
in 300 ml DME plus 5% fetal calf serum. To generate CM, the ceils were 
washed three times and incubated in serum-free DME (175 ml) for 2-3 d. 
CM was centrifuged to remove debris and stored at  -20°C. 
The CM was ultraliltered using an Amicon YM-30 membrane, and the 
<30-kD filtrate was chromatographed on BioRex-79 (Bio-Rad Laborato- 
ries, Cambridge, MA), a weak cation exchanger. 700 ml of filtrate was ap- 
plied to a 40 rrd bed BioRex-70 column equilibrated in Tris buffer (20 raM, 
pH 7.5). The column was washed with 200 ml of buffer and eluted with 200 
nd of 1.5 M NaC] in "Iris buffer. The eluate was de-salted by dialysis, using 
a 1-kD membrane, and applied to a 10 rnJ bed (0.9 cmx  15 cm) BioRex-70 
column. This column was washed with Tris buffer and eluted using a 30 
ml NaCI gradient (0-1.5 M) at '~1.5 nd/min. 1-ml fractions were collected, 
and the fractions were dialyzed, lyophilized, re-hydrated, and assayed for 
SF-IF activity using MRC5 as target cells. 
Active fractions were pooled and applied to an HR10/10 PepRPC FPLC 
column (8 ml bed volume) (Pharmacia Fine Chemicals, Piscataway, NJ) in 
a sample volume of 0.5 ml. The column was eluted with a 0-100% gradient 
of acetonitrile in water (containing 0.1 g/1 of trifluoroacetic acid [TFA]) at 
1.0 ml/min for 30 rain, and 1.0 ml fractions were collected. Fractions were 
lyophilized, rehydrated, and assayed for SF-IF activity. Active fractions 
were re-chrornatographed on the same column, yielding a single peak of 
absorbance.  An aliquot of this peak was applied to a  narrow-bore C18 
HPLC column. This column was eluted with a gradient of acetonitrile in 
water (plus TFA), at a rate of •1%  per min. Peaks containing protein were 
lyophilized, rehydrated, and used for bioassays and SDS-PAGE analysis. 
Protein was assessed by absorbance at 280 nm (and at 214 nm at the final 
stage of purification),  and by the Bio-Rad dye-binding microassay.  Ui- 
trafiltration and standard chromatography were performed at 4°C, while 
FPLC and HPLC were performed at 25°C. An aliquot of highly purified 
SF-IF from the C18 HPLC column was used for direct amino acid microse- 
quencing. Sequence analysis was performed at the Laboratory for Molecu- 
lar Analysis (Albert Einstein College of Medicine). 
Elution of SF-IF  Activity from Gel Slices 
Ras-3T3  SF-IF  partially  purified on  BioRex-70  (t.5  ml)  was  analyzed 
preparatively on a  15%  SDS-polyacrylamide gel, using a slot width of 8 
cm, without reduction. The unstained gel was sectioned into 4 mm slices, 
and each slice was crushed and eluted by passive diffusion for 48 h at 4"C 
in 2 ml of 3 mM NI~-ICO3 buffer, pH 8. Eluates were dialyzed, dried, re- 
hydrated in 50/zl of DME, and assayed for SF-IF activity using MRC5 cells. 
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Figure 1.  (A) Effects of differ- 
ent  fractions of ras-3T3 CM 
on SF production by CCDI 1 l- 
Lu  human  fibroblasts.  CM 
was  chromatographed  on 
S-Sepharose  to  remove  SE 
and the SF-free void was sep- 
arated into >30- and <30-kD 
fractions  by  ultra filtration. 
Fractions  were  assayed  for 
stimulation  of production  of 
SF activity by CCDI 1Lu. Val- 
ues  are  means  +  SEMs  of 
triplicate assays. (B) Stimula- 
tion of ras-3T3 SF production 
by  partially  purified  ras-3T3 
SF-IE The ras-3T3 CM <30- 
kD filtrate was partially puri- 
fied using BioRex-70 (see Ma- 
terials and Methods). The Bio- 
Rex-70  eluate  was  dialyzed, 
lyophilized,  re-hydrated  in 
DME, and assayed for stimu- 
lation of SF production by ras- 
3"I"3 cells.  Two different col- 
lection  volumes  were  used 
(see Figure). The response of 
CCDI1Lu  cells  is  shown  for 
comparison. Values are means 
of duplicate assays, with ranges 
within  -t-15%  of the means. 
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SF-IF activity* 
Treatment  (Percent of control) 
Control (no treatment)  100 
Ultrafiltration 
>30-kD retentate  4  +  4 
<30-kD filtrate  100  +  12 
Dialysis 
Undialyzed  100  +  4 
l-kD membrane  141  +  47 
5-kD membrane  80  + 
12-14-kD membrane  3  +  3 
25-kD membrane  0 
Heat (100°C  x  5 min)  126 
pH (2 h at 25°C) 
1.0  57  +  5 
3.0  84  +  6 
7.0  100  ±  9 
10.0  93  +  7 
12.0  96  ±  6 
Proteases~ 
Trypsin  0 
Pronase  0 
Reductive  alkylationll  100 
* Activity is  expressed relative to  that of ras-3T3 CM  <30-kD filtrate 
(control). 
Ultrafiltration. CM was separated  into <30- and >30-kD fractions  using an 
Amicon  YM-30 filter. The >30-kD retentate  was chromatographed  on S-Seph- 
arose to remove SF prior to assay for SF-IF. 
§  Protease treatment. Trypsin. Samples  were incubated with bovine trypsin 
(50 #g/ml) for 60 min at 37°C, and soybean  trypsin  inhibitor  (100/~g/ml) was 
added. For controls, soybean trypsin inhibitor was added before trypsin. 
Pronase. Samples were concentrated 100-fold and incubated with 0.2 U/ml 
pronase (Sigma  P-0652) for 24 h at 37°C. Pronase  activity  was stopped  by di- 
lution or by boiling for 5 min. Controls without pronase were treated iden- 
tically. 
II Reductive  alkylation. SF-IF was incubated  with DTT (5 mM) for 90 min at 
37°C; and then with iodoacetamide  (10 mM) for 60 min at 370C. Factor was 
dialyzed  using  a 1-kD  membrane, to remove  DTT and iodoacetamide.  Controls 
were incubated without DTT or iodoacetamide  and dialyzed  similarly. 
Results 
Stimulation of SF Production by Human 
Tumor Cell CM 
We screened CM  from multiple lines of breast carcinoma 
cells for SF-inducing activity (defined as the ability to stimu- 
late human fibroblast SF production by more than twofold). 
None of  the CM samples contained any SF detectable by bio- 
assay or ELISA.  However,  eight out of nine  CM  samples 
contained SF-inducing activity (Table I). These CM samples 
induced the production of SF biologic activity, protein, and 
mRNA (see below). To further characterize the SF-inducing 
activity,  CM  samples  were  ultrafiltered using  an  Amicon 
YM-30 membrane. Both the <30-kD filtrate and the >30-kD 
retentate  contained  SF-inducing  activity;  but  the  relative 
proportions of these activities varied among  different cell 
lines. The >30-kD SF-IF activity was completely destroyed 
by boiling (100°C  x  5 min), while the <30-kD activity was 
heat stable (not shown).  Both activities were abolished by 
treatment with trypsin. In addition to breast carcinoma cells, 
we detected high and low molecular weight SF-IF activities 
Figure 2.  Stimulation of SF 
mRNA expression in CCD11- 
Lu fibroblast cultures by ras- 
3T3  CM  <30  kDa  filtrate. 
Confluent cultures were incu- 
bated for 24 hr with different 
concentrations of ras-3T3 fil- 
trate. The total cell RNA was 
extracted, and equal aliquots 
of RNA (20 #g per lane) were 
electrophoresed and Northern 
blotted. Blots were probed us- 
ing  a  cDNA  for  human  SF 
(panel A).  As a  control,  the 
blots  were  stripped  and  re- 
probed  for  28S  ribosomal 
RNA  expression  (panel  B). 
The  concentrations of SF  in 
the culture medium were de- 
termined by ELISA (panel C). 
in CM from other tumor types (see below), suggesting that 
tumor cells produce at least two distinct SF-IF activities. 
Stimulation of SF Production by Factors 
in ras-3T3 CM 
Ras-3T3 (D4) is a line of mouse fibroblasts that produces ex- 
tremely high titers of SF. While determining the optimal con- 
ditions for collection of ras-3T3  CM for purification of SF 
(Rosen et al., 1990a), we found that the total SF production 
was inversely related to the volume of collection medium. 
Similar relationships between  SF  production  and  volume 
were observed for three lines of normal human  fibroblasts 
(CCDllLu,  WI38,  CCL33Lu).  SF production  rates  were 
(2.5-3)-fold greater at small volumes  (0.1  ml/cm  2) than  at 
large volumes (>t0.5  ml/cm2).  These results suggested that 
SF production by fibroblasts might be regulated, in part, by 
the accumulation of a  soluble SF-inducing factor(s). 
To determine if ras-3T3 CM contained SF-IF activity, SF 
was removed from the medium, selectively, by chromatogra- 
phy on S-Sepharose fast flow (Pharmacia Fine Chemicals), 
a resin with high affinity for SF (Rosen et al.,  1990a).  At a 
CM/bed  volume  ratio  of  50:1,  the  S-Sepharose  column 
bound all of the SF activity but only 1% of the total protein. 
No SF was found in the void fraction. The SF-free ras-3T3 
void was filter-sterilized and assayed for SF-inducing activ- 
ity.  Addition of ras-3T3  void  induced  dose-dependent  in- 
creases  in  SF  production  rate  by  multiple  SF-producing 
fibroblasts lines (Fig. 1, and see below). To quantitate SF-IF 
activity, one SF-IF U/ml was defined as the dose of SF-IF 
needed to double the rate of SF production by human lung 
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blast cultures treated without or with ras-3T3 CM <30 kDa filtrate. 
Confluent CCDI 1Lu cultures were incubated for various times up 
to 72 h without (control) or with 10% (v/v) of ras-3T3 CM <30 
kDa filtrate, the total cell RNA was extracted, electrophoresed (20 
#g per lane), and Northern blotted. Panel A shows SF mRNA ex- 
pression; panel B shows 28S ribosomal RNA expression; and panel 
C shows the densitometric ratios of SF(6 kb)/28S for control and 
ras-3T3 (SF-IF)-treated cells. 
fibroblasts (CCDllLu or MRC5). The titer of SF-IF activity 
in  ras-3T3 CM  S-Sepharose void (60-70 U/ml)  was  con- 
siderably higher than the titers found in human tumor cell 
CM  (2-18 units/ml).  Thus, ras-3T3  cells were utilized for 
further characterization of the SF-IF activity. 
Properties of ras-3T3 SF-IF Activity 
After  fractionation using  an  Amicon  YM-30  membrane, 
nearly all of the SF-IF activity was found in the <30-kD 
filtrate (Table II,  Fig.  1 A).  Subsequent studies were per- 
formed using the <30-kD filtrate without S-Sepharose chro- 
matography, since no SF was present in these filtrates, and 
since they contained the same SF-IF activity as the S-Sepha- 
rose void. Most of  the SF-IF activity was retained after dialy- 
sis using 1- and 5-kD membranes, whereas little or no activ- 
ity was retained by 12-14 or 25-kD membranes (Table II). 
SF-IF activity was  stable to boiling,  reductive alkylation, 
and exposure to a wide range of pH values. Treatment with 
proteases (trypsin or pronase) destroyed the activity. These 
data suggest that the SF-IF activity is due to a  stable, low 
molecular weight (5-15 kD) protein(s). There was no differ- 
ence in SF-IF activity whether the assays were performed 
without  or  with  serum.  Neither  crude  CM  nor  highly 
purified ras-3T3 SF-IF had a significant effect on the fibro- 
blast cell number. There was no evidence of target fibroblast 
toxicity, as judged by morphology or exclusion of trypan 
blue dye. 
Sensitivity of Different Lines of Fibroblasts 
of SF-IF Activity 
Six of six human lung fibroblast lines (CCDllLu,  MRC5, 
WI38, CCD32Lu, CCL33Lu, CCL215)were responsive to 
ras-3T3 CM <30-kD filtrate. The concentrations of filtrate 
(vol/vol) required to double the rate of SF production were 
generally similar (1.5-3 %). The maximum stimulation of SF 
production, relative to control, was four- to sixfold. These 
maximum responses were observed at 10-25 % filtrate. Ras- 
3T3 cells themselves were responsive to partially purified 
ras-3T3  SF-IF  activity  (BioRex-70  fraction)  (Fig.  1  B). 
When assayed using the same collection volume (0.25 ml/ 
cm2),  ras-3T3  cells were less  sensitive to BioRex fraction 
than were CCDllLu human fibroblasts (Fig. 1 B). However, 
increasing the collection volume from 0.25 to 0.75 ml/cm  2 
resulted in increased sensitivity of ras-3T3 cells to BioRex 
fraction. The doses of  BioRex fraction required to double the 
SF production rate were 0.10, 0.13, and 0.47% (vol/vol), re- 
spectively, for ras-3T3  (V  =  0.75 ml/cm2), CCDllLu (0.25 
ml/cm2), and ras-3T3 (0.25 ml/cm2). The apparent reduced 
sensitivity of ras-3T3 cells to exogenous factor at the smaller 
collection volume may reflect the high rate of endogenous 
production of SF-IF activity by these cells. 
Effect of SF-IF Activity on SF raRNA Expression 
Treatment of human fibroblasts with ras-3T3 CM <30-kD 
filtrate resulted in coordinate increases in expression of all 
SF mRNA species, although in most experiments, only the 
more abundant  6-  and  3-kb  mRNs  were visualized well. 
Treatment of CCDllLu cells for 24 h with ras-3T3 filtrate 
induced a dose-dependent increase in the SF mRNA expres- 
sion, with maximal responses at 10-25 % filtrate (vol/vol) in 
different experiments (Fig. 2 A). Corresponding increases in 
SF protein, as determined by ELISA, were also observed 
(Fig. 2 C). SF mRNA expression increased within 6 h after 
addition of ras-3T3 filtrate, peaked at 18 h, and then declined 
slowly, but remained above control levels at 72 h (Fig. 3 A). 
Control cultures also showed time-dependent increases in SF 
mRNA expression that were smaller in magnitude than for 
treated cultures (Fig. 3 A). Similar time-dependent changes 
in SF mRNA expression in control cultures were observed 
in other experiments; these changes may be due, in part, to 
an endogenous SF inducer (see below). After 48-72 h, ex- 
pression of the 6-kb SF mRNA was about three- to fourfold 
higher in treated cultures than in control cultures (Fig. 3 C). 
These increases  in  SF mRNA  expression correlated with 
four- to sixfold increases in SF protein production, deter- 
mined by ELISA (data not shown). Similar to ras-3T3 CM, 
media from various lines of human  mammary carcinoma 
cells (see Table I) also stimulated SF mRNA expression. SF 
itself (20  ng/ml)  did  not  affect SF  mRNA  expression in 
CCDllLu fibroblasts (not shown). 
SF-IF Producer and Responder Cell 7)jpes 
CM from six of six lines of SF-producing human fibroblasts 
contained <30-kD SF-IF-like activity. However, the activity 
titers (4-10 U/ml) were much less than that in ras-3T3 CM 
(60-70 U/ml). Three lines of non-SF-producing fibroblasts 
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Cell line  Cell type  SF production  SF-1F production  SF-IF response 
Ras-3T3 (D4)  Mouse fibroblast  +  +  + 
CCD11Lu  Human lung fibroblast  +  +  + 
CCD32Lu  "  +  +  + 
CCL33Lu  "  +  +  + 
WI38  "  +  +  + 
CCL215  "  +  +  + 
MRC5  "  +  +  + 
3AsubE SV40 tx  Human placenta fibroblast  -  -  - 
BALB/c-3T3  Mouse fibroblast  -  -  - 
Swiss albino 3T3  "  -  -  - 
Bac2F5  Mouse macrophage  +  -  - 
Human macrophage  +  -  - 
RASM  Rat aorta smooth muscle  +  -  + 
U87MG  Human glioblastoma  +  +  + 
Hs683  "  +  +  + 
Bovine pericyte  -  -  - 
C2  Rat hepatoma  -  -  - 
SKBr3  Human mammary carcinoma  -  +  - 
MCF7  "  -  +  - 
BT549  "  -  +  - 
MDA23  "  -  +  - 
MDA468  "  -  +  - 
Hs578T  ..... 
T47D  "  -  +  - 
173T  "  -  +  - 
186TL  "  -  +  - 
YaOvBix2NMA  Human ovary carcinoma  -  -  - 
SKOV3  ..... 
HEY  ..... 
MDCK  Canine kidney epithelium  -  -  - 
A253  Human squamous carcinoma  -  -  - 
Calu 1  ..... 
WW943  Human melanoma  -  -  - 
MeWo  "  -  -  - 
Zazzaro  "  -  -  - 
* To assay for SF-IF production,  confluent test cells were incubated with serum-free DME (0.1 ml/cm  2) for 48 h to generate CM.  The CM was assayed for its 
ability to stimulate SF production by human lung fibroblasts. For cell types that produce SF, the <30-kD filtrate of the CM was assayed. (+) Greater than twofold 
stimulation of SF production. (-) denotes no stimulation of SF production at up to 50% test CM (i.e.,  <2 SF-IF units/ml). To assay for response to SF-IF, confluent 
test cells were incubated with different concentrations of ras-3T3  <30-kD filtrate for 48 h in 2 em  2 wells (0.5 ml of DME per well), and the SF production rates 
were determined. (+) Greater than twofold stimulation of SF production by the test cells. (-) No response at up to 25 % ras-3T3 <30-kD filtrate ( 15 U/ml of SF-IF). 
(BALB/c-3T3,  Swiss albino 3T3,  3ASubE) did not produce 
any  detectable  SF-IF  activity.  In  addition  to  breast carci- 
noma cells, two lines of human glioblastoma cells produced 
SF-IF  activity.  On the other hand,  no SF-inducing activity 
was found in CM  from macrophages,  bovine pericytes,  rat 
hepatoma cells, MDCK  epithelial cells, two lines of human 
squamous  carcinoma cells,  three lines of ovary carcinoma 
cells, and three lines of melanoma cells. Seven of seven SF- 
producing lines of fibroblasts responded to ras-3T3 CM.  In 
contrast, multiple non-SF-producing lines of fibroblasts, ep- 
ithelial cells, and tumor cells did not produce detectable lev- 
els  of SF  in response  to ras-3T3 CM  (Table III).  The  re- 
sponses  of various  stromal  cell  types  to  purified  SF-IF  is 
described below. 
Ras-3T3 SF-IF  Activity Is Distinct  from IL  4 
IL-1 was reported to stimulate SF production by human der- 
mal and lung fibroblasts (Matsumoto et al.,  1992a;  Tamura 
et al.,  1993).  We found that recombinant murine IL-lc~, hu- 
man IL-lot, and human IL-1/~ each stimulated production of 
SF activity, protein, and mRNA  by CCDllLu  cells.  A  dou- 
bling of SF production required ~0.1-0.2 ng/ml, while maxi- 
mal  (fourfold)  stimulation  of SF  production  required  I>2 
ng/ml of IL-1  (not shown).  We used a  sensitive bioassay to 
quantitate IL-1  biologic  activity  (see  Materials  and Meth- 
ods).  Ras-3T3  S-sepharose  void and ras-3T3  CM  <30-kD 
filtrate, which contained 60-70 U/ml of SF-inducing activ- 
ity, had no detectable IL-1 activity. The BioRex-70 fraction, 
which contained 1,000 U/ml of SF-IF activity, had IL-l-like 
activity.  The  BioRex-70  fraction,  which  contained  1,000 
U/m1 of SF-IF activity, had IL-l-like activity corresponding 
to only 12 pg/ml of recombinant mouse IL-lct.  Further evi- 
dence that SF-IF  and IL-1  are distinct is presented below. 
Effects of Other Cytokines and Growth Factors 
on SF Production 
We  screened  a  variety  of factors  for  SF-inducing  activity 
using various SF-producing human cell types as target cells, 
including MRC5  lung fibroblasts, mammary  tumor-derived 
fibroblasts  (l136TF),  and  glioblastoma  cells  (U87MG, 
Hs683)  (Table IV).  Recombinant human IL-lct,  human IL- 
1/~, mouse IL-lo~, and human TNFc~ gave maximal stimula- 
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(MRC5 Human Lung Fibroblasts,  U87MG,  and Hs683 
Human Glioblastoma  Cells,  1136TF Human Mammary 
Tumor-derived Fibroblasts)  to Purified SF-IF* and to 
Various  Other Cytokines 
SF production rate* 
Agent  MRC5  U87MG  Hs683  1136TF 
(ng/ml)  (ng/lO 6 cells~24 h) 
Control  (0)  5.1  1.0  5.0  2.4 
ras-3T3 SF-IF  (5)  25.0  4.5  11.8  12.6 
IL-lc~  (5)  14.1  0.7  5.8  2.7 
IL-1/3  (5)  11.2  1.0  4.8  2.3 
IL-6  (20)  5.0  0.9  4.7  2.1 
IL8  (20)  7.0  1.0  4.5  2.2 
ILll  (20)  5.8  NT  NT  2.5 
TNFct  (20)  13.7  1.3  3.1  2.2 
Oncostatin-M  (20)  6.9  1.4  4.1  3.4 
Basic FGF  (20)  8.7  0.9  3.7  1.9 
EGF  (20)  6.0  0.8  6.3  2.8 
* Ras-3T3  SF-IF was purified  as described in the text. Confluent target ceils 
in 2-cm  2 wells were incubated in 0.5 ml of serum-free DME containing vari- 
ous agents for 48 h, and SF was measured by ELISA. Values are averages of 
two assays (range -I-15% of the mean). 
tion of SF production by MRC5 cells at concentrations of 5, 
5, 5, and 20 ng/ml, respectively. However,  neither of these 
agents alone or in combination stimulated SF production by 
U87MG,  Hs683, or l136TF (Table IV).  EGF, basic FGF, 
PDGF, oncostatin-M, and various interleukins and interfe- 
rons did not stimulate SF production by any of these cell 
types. In a separate set of experiments, we tested the ability 
of various factors to stimulate SF production by CCD11Lu 
human lung fibroblasts.  Each agent was studied over a range 
of concentrations (up to 20 ng/ml for purified cytokines). 
The following agents had no effect on SF production: EGF, 
TGFo~ PDGF, basic FGF, bovine pituitary extract (which 
contains a mixture of acidic and basic FGFs), keratinocyte 
growth factor, mast cell growth factor, CSF-1, vascular en- 
dothelial cell growth factor, oncostatin-M, lipopolysaccha- 
ride (endotoxin), interferon-% various interleukins (IL-2, 
IL-4, IL-6, IL-7, IL-8, IL-11), fetal calf serum, and calf se- 
rum. TNFct induced a small increase in SF production but 
did not stimulate SF mRNA expression in CCDllLu. TGF/~, 
a known inhibitor of SF expression (Gohda et al.,  1992), 
blocked basal and ras-3T3 CM-stimulated SF production. 
Purification of SF-IF 
We purified SF-IF from ras-3T3 CM using a combination of 
ultrafiltration, cation exchange chromatography, and reverse 
phase chromatography (RPC) (Fig. 4 and Table V). Further 
chromatography of the active PepRPC fractions (see Fig. 4 
B) on a C18 HPLC column revealed one major protein peak 
containing all of the SF-IF activity (Fig. 5). Highly purified 
SF-IF from PepRPC columns exhibited relative molecular 
mass values of 14 +  2 kD under nonreducing conditions and 
12  +  2  kD  under  reducing conditions on  silver-stained 
SDS-polyacrylamide gels (Fig. 6).  SDS-PAGE  analysis of 
C18  HPLC-purified  SF-IF  revealed  the  same  band  (not 
shown). The identity of this protein was verified by elution 
of  SF-IF  activity  from  SDS-polyacrylamide  gel  slices. 
Nearly all of the activity recovered from the gel was found 
in the gel slice corresponding to about 14 kD (nonreduced). 
A dose-response curve for the purified factor is presented 
in Fig. 4 B (inset).  Based on these and other dose-response 
data and the relative molecular mass of the purified factor, 
as determined by SDS-PAGE, we estimate that twofold stim- 
ulation of MRC5 SF production requires about 15-25 pM of 
SF-IE and maximal stimulation of SF production requires 
300-500 pM of SF-IE Highly purified ras-3T3 SF-IF stimu- 
lated SF by human lung fibroblasts, mammary fibroblasts, 
and glial cells, as demonstrated by ELISA (Table IV) and 
Western blotting (Fig. 7). 
Direct sequencing of an aliquot of purified SF-IF from the 
HPLC column revealed a  single NH2-terminal  sequence: 
AKNDAIKIGA. This sequence did not match or show close 
homology with any sequences in the Protein Identification 
Resource, Swiss-Prot, GeneBank, or GenEMBL databases, 
suggesting that SF-IF is a new and unique protein. 
Discussion 
We have presented evidence that autocrine and paracrine 
mechanisms involving soluble-inducing factors regulate SF 
production by fibroblasts and other stromal cell types. We 
have provided a detailed characterization of one such factor 
produced by a line of ms-transformed mouse 3T3 cells that 
overexpresses SE  This SF-inducing factor is a heat stable 
protein with a molecular size of about 12 +  2 kD (reduced) 
by SDS-PAGE  with silver staining. SF-IF activity was not 
detected in fetal calf serum; and the production of and re- 
sponse to SF-IF did not require serum. 
Table  V.  Purification  of ras-3T3 SF-IF* 
Step  Activity  Protein  Spec.  Act.  Fold purification  Recovery 
(u)  (~g)  (U/~g)  (%) 
Ras-3T3 CM (700 ml)  46,000  84,000  0.5  1  100 
Ultrafiltration  46,000  28,000  1.6  3  100 
1st BioRex column  33,600  840  40  80  73 
2nd BioRex column  28,000  165  170  340  61 
PepRPC (C2/18 FPLC)  15,000  5  3,000  6,000  33 
HPLC (C18)¢  1,500  0.31  4,840  9,680  - 
* SF-IF was purified as described in the Materials and Methods section. Chromatographic fractions were dialyzed, lyophilized,  rehydrated, and assayed for SF-IF 
activity using MRC5 fibroblasts. 
¢ An aliquot of the FPLC peak containing biologic activity was subjected to chromatography on a narrow-bore C18 HPLC column. 
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Figure  4.  Purification of ras- 
3T3  SF-IF. The ras-3T3 CM 
<30 kDa filtrate (700 ml) was 
chromatographed  twice  on 
BioRex-70. The  second  Bio- 
Rex-70  column  was  eluted 
with an NaCI gradient  (panel 
A).  Fractions  containing  SF- 
IF activity (shaded area) were 
pooled  and  applied  to  a  re- 
verse phase FPLC (PepRPC) 
column (panel B). RPC frac- 
tions were dried, rehydrated in 
50 #1 of DMEM, and assayed 
for biologic activity. All of  the 
SF-IF activity was eluted in a 
small peak at about 45% ace- 
tonitrile  (shaded  area).  The 
inset  shows  a  dose-response 
curve for stimulation of  MRC5 
SF  production  by  purified 
SF-IF. 
We found that human mammary tumor and glioblastoma 
cells produce soluble high  and low  molecular weight  SF- 
inducing factors.  Seslar and colleagues (1993) reported that 
MCF7 breast carcinoma cells secrete an activity that stimu- 
lates SF protein and mRNA expression by MRC5 fibroblasts. 
This activity was >30 kD and heat sensitive, similar to the 
high molecular weight inducer that we detected, but distinct 
from the factor that we purified. Ras-3T3 SF-IF stimulated 
expression of SF in several stromal cell types, including lung 
fibroblasts,  mammary  tumor  fibroblasts,  and  glial  cells. 
0.30 
Thus,  stromal  cells  stimulated  by  SF-IFs  may  be  a  rich 
source of SF production within tumors. This hypothesis is 
supported by the finding that large quantities of both SF and 
SF-inducing activity are present in extracts of solid EMT6 
mouse  mammary tumors  (Rosen  et  al.,  1994).  Cultured 
EMT6  cells did  not produce  SE  but  did  produce an  SF- 
IF-like activity for fibroblasts. Interactions between epithe- 
lial and stromal cells are thought to regulate the expression 
of urokinase and metalloproteinases, enzymes that potentiate 
tumor cell invasion (van den Hooff, 1988).  SF is a very po- 
tent stimulator of tumor cell motility, protease expression, 
and invasion (Rosen et al., 1990b,  1991; Weidner et al., 1990; 
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Figure 5.  C18 reverse phase HPLC of SF-IE  An aliquot of SFoIF 
from the PepRPC column (Fig. 4 B) was analyzed on a narrow-bore 
C18 HPLC column. The major peak, which eluted at 41% acetoni- 
trile, contained SF-IF biologic activity (shaded area).  None of the 
minor peaks contained detectable activity. 
Figure 6. SDS-PAGE  of  highly 
purified SF-IF. SF-IF purified 
from ras-3T3  CM  (PepRPC, 
Fig,  4 B) was analyzed on a 
silver-stained  15 % SDS-POly- 
acrylamide  gel  with  [+ME 
(mercaptoethanol)]  and with- 
out (-ME) reduction. Lane 1 
and lanes  (2+3)  show SF-IF 
from  two  different  purifica- 
tions. The positions of the re- 
duced molecular weight stan- 
dards  are  indicated  on  the 
right, 
The Journal of Ce|l Biology, Volume 127,  ~994  232 Figure 7. Western blotting of CM from SF-producing cells treated 
with purified SF-IF. Confluent U87MG glioblastoma cells and 
MRC5 fibroblasts were incubated in DMEM (10 ml/100 mm dish) 
+ SF-IF for 24 h. The CM was concentrated and blotted to detect 
SE Lanes 1-3 represent U87MG; lanes 4-6 represent MRC5. The 
doses of SF-IF were 0 (lanes 1 and 4), 1.2 ng/ml (lanes 2 and 5), 
and 5 ng/ml (lanes 3 and 6). The arrow shows  the position of  recom- 
binant human SE 
Rosen et al., 1994). SF is also a potent mediator of  pathologic 
angiogenesis (Grant et al.,  1993;  Naidu et al.,  1994).  Our 
studies provide a further mechanism by which tumor:stroma 
interactions may contribute to malignant growth. 
IL-1  and TNF, two multi  functional cytokines associated 
with tissue response to injury, were reported to stimulate SF 
production by some human fibroblast lines (Matsumoto et 
al.,  1992a; Tamura et ai., 1993).  We observed increases in 
SF protein and mRNA expression in multiple IL-l-treated 
human lung fibroblast lines (unpublished results). However, 
IL-1, TNF, and combinations of  IL-1 plus TNF did not stimu- 
late SF production in several other stormal cell types respon- 
sive to purified SF-IF (Table IV). Using a sensitive bioassay 
of IL-1, crude preparations of ras-3T3 CM, which contained 
large amounts of SF-IF activity, contained little or no IL-1. 
Partially purified  SF-IF  (BioRex  fraction)  contained the 
equivalent of 12 pg/ml of IL-1. Based on the ability of IL-1 
to  stimulate  MRC5  SF  production,  the  amount of IL-1 
needed to account for the SF-IF activity in the BioRex frac- 
tion would be about 1,000 SF-IF U/ml x  (0.1-0.2 ng/ml)/SF- 
IF U  =  100-200 ng/ml (8,300-16,600  times the measured 
quantity). This calculation is subject to uncertainty due to 
the potential influence of other inhibitory or synergistic mol- 
ecules in the preparation. Nonetheless, it suggests that IL-1 
can account for only a  small fraction of the SF-IF activ- 
ity produced by ras-3T3 cells. Finally, the aminoterminal se- 
quence of purified SF-IF did not match any known protein. 
SF-IF may be a prototype of a specific class of physiologic 
regulators of SF production. 
A protein activity that accumulates in rat serum after liver 
injury stimulates SF mRNA expression of SF mRNA in rat 
lung tissue and in MRC5 fibroblast cultures (Matsumoto et 
al., 1992b).  The factor(s) responsible for this activity, called 
injurin, is a heat stable and trypsin-sensitive protein(s) with 
relative molecular mass of 10-30 kD, as determined by gel 
filtration chromatography and by elution of activity from an 
SDS-polyacrylamide gel,  The  source  of injurin  was  not 
identified, but its appearance in the serum within several 
hours of organ injury suggests an endocrine mechanism for 
regulation of SF production. SF-IF has several properties in 
common with injurin, but a more definitive comparison is 
not  possible  since  purification  of  injurin  has  not  been 
reported. 
Interestingly, various carcinoma cell lines that produce 
SF-inducing activity are unable to produce SF themselves 
(Table I). Since SF-IF is active at physiologic (picomolar) 
concentrations, it is likely that this  factor acts through a 
specific cellular receptor. Thus, cells that produce SF-IF but 
not SF may lack the putative SF-IF receptor. Alternatively, 
these cells may be missing other components of the mecha- 
nism required for the expression of SF.  In studies of cell 
types that produce  SF,  Stoker and colleagues (1987)  ob- 
served that different lines of fibroblasts produced widely 
varying titers of SE Even among strains of mouse 3T3 cells, 
the levels of SF production ranged from undetectable to very 
high. We can now postulate that differences in SF production 
rates  result  from  differences in  the  expression  of SF-IF 
and/or  its  receptor.  This  hypothesis is  supported  by  the 
finding that three lines of non-SF-producing fibroblasts nei- 
ther produced nor responded to SF-IF, while seven lines of 
SF-producing fibroblasts all produced detectable SF-IF ac- 
tivity. 
In conclusion, we showed that SF production is regulated 
by autocrine and paracrine mechanisms involving a soluble 
low molecular weight protein that acts at picomolar concen- 
trations. This scatter factor-inducing factor acts across spe- 
cies barriers and is biologically active on several stromal cell 
types.  We suggest that SF-IF is an important physiologic 
regulator of SF production. 
Supported in part by research grants from the United States Public Health 
Service  (ROICA50516)  and the American Cancer Society  (BE-7).  Dr. 
Rosen is an Established Investigator of the American Heart Association. 
Received for publication 19 April 1994 and in revised form 29 June 1994. 
References 
Adams, J. C., R. A. Furlong, and F. M. Watt. 1991. Production of scatter fac- 
tor by ndk, a strain of epithelial  cells, and inhibition of scatter factor activity 
by suramin. J.  Cell Sci.  98:385-394. 
Bharguva, M., A. Joseph, J. Knesel, R. I-Ialaban, Y. Li, S. Pang, I. Goldberg, 
E.  Setter,  M.  A,  Donovan,  R.  Zarnegar,  G.  A.  Michalopoulos,  T. 
Nakamura, D. Faletto, and E. M. Rosen. 1992. Scatter factor and hepatocyte 
growth factor:  Activities, properties, and mechanism. Cell Growth Differen. 
3:11-20. 
Bottaro, D. P., J.  S. Rnhin, D. L. Faletto, A. M.-L Chart,  T. E. Kmiecik, 
G. F. V ande Woude, and S. A. Aaronson. 1991. Identification  of  the hepato- 
cyte growth factor receptor as the c-met proto-oncogene product. Science 
(Wash.  DC).  251:802-804. 
Bussolino, F., M. F. DiRenzo, M. Ziche, E. Bocchietto, M. Olivero, L. Nal- 
dini, G. Gaudino, L. Tamagnone,  A. Coffer, and P.M. Comoglio. 1992. He- 
patocyte growth factor is a potent angiogenic factor which stimulates en- 
dothelial cell motility and growth. J.  Cell Biol.  119:629-641. 
Chan, A. M.-L., J. S. Rubin, D. P. Bottaro, D. W. Hirschfield, M. Chedid, 
and S. A. Aaronson. 1991. Identification  of  a competitive antagonist  encoded 
by an alternative transcript. Science (Wash.  DC).  254:1382-1385. 
Chomczynski, P., and N. Sacchi. 1987.  Single-step method of RNA isolation 
by  acid  guanidinium isothiocyanate-phenol-chloroform extraction.  Anal. 
Biochem.  162:156-159. 
Elias, J. A., and V. Lentz. 1990. IL-1 and tumor necrosis factor synergistically 
stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA. J. 
Invnunol.  145:161-166. 
Erikson, J.  M.,  C.  L.  Rushford, D.  J.  Doroey, G.  N.  Wilson, and R.  D. 
Schmickel. 1981. Structure and variation of human ribosomal DNA: molec- 
ular analysis of cloned fragments. Gene.  16:1-9. 
Furlong, R. A., T. Takheara, W. G. Taylor, T. Nakamura, and J. S. Rubin. 
1991. Comparison of biologic and immunochemical  properties indicate that 
scatter factor and hepatocyte growth factor are indistinguishable.  J. Cell Sci. 
100:173-177. 
Gherardi,  E.,  J.  Gray,  M.  Stoker,  M.  Perryman,  and R.  Furlong.  1989. 
Purification  of scatter factor, a fibroblast-derived basic protein which modu- 
lates epithelial  interactions and movement. Proc.  Natl.  Acad.  Sci.  USA. 
86:5844-5848. 
Gnhda, E., T. Matsunaga, H. Kataoka, and I. Yamamoto. 1992. TGF-~ is a 
potent inhibitor of hepatocyte growth factor secretion by human fibroblasts. 
Cell Biol.  Int.  Rep.  16:917-926. 
Grant, D. S., H. K. Kleinman, I. D. Goldberg, M. Bhargava, B. J. Nickoloff, 
P. Polverini, and E. M. Rosen. 1993. Scatter factor induces  blood vessel for- 
marion in vivo. Proc. Natl. Acad.  Sci.  USA.  90:1937-1941. 
Hopkins, S. J., and M. Humphreys. 1989. Simple, sensitive and specific bioas- 
Rosen et al. Regulation of Scatter Factor Production  233 say of interleukin-1. J. Immunol.  Methods.  120:271-276. 
Matsumoto, K., and T. Nakaraum. 1993. Roles of HGF as a pleiotropie factor 
in organ regeneration. In Hepatocyte Growth Factor-Scatter Factor and the 
c-Met Receptor.  I.  D.  Goldberg, and E.  M.  Rosen, editors.  Birkhauser- 
Verlag, Basel. 225-250. 
Matsumoto, K., H. Okazaki, and T. Nakamura. 1992a. Up-regulation of hepa- 
tocyte growth factor gene expression by interleukin-I in human skin fibro- 
blasts. Biochem.  Biophys.  ICes. Commun.  188:235-243. 
Matsumoto, K., H. Tajima, M. Hamanoue, S. Kohno, T. Kinoshitu, and T. 
Nakamura.  1992b.  Identification  and characterization of "injurin  ", an in- 
ducer of expression of the gene for hepatocyte growth factor. Proc. Natl. 
Acad.  Sci.  USA.  89:3800-3804. 
Miyazawa,  K.,  H.  Tsubouchi, D.  Naka,  K.  Takahashi,  M.  Okigaki,  N. 
Arakaki, H. Nakayama, S. Hirono, O. Sakiyama, E. Gohda, Y. Dalkuhara, 
and N. Kitamura. 1989. Molecular cloning and sequence analysis of cDNA 
for human hepatocyte growth factor.  Biochem.  Biophys.  Res.  Commun. 
163:967-973. 
Montesano, R., K. Matsumoto, T. Nakamura, and L. Orci. 1991. Identification 
of a fibroblast-derived  epithelial  morphogen as hepatocyte growth factor. 
Cell.  67:901-908. 
Naidu, Y. M., E. M. Rosen, R. Zitnik, L Goldberg, M. Park, M. Naujokas, 
P. J. Polverini, and B. J. Nickoloff.  1994. Role of scatter factor in the patho- 
genesis of AIDS-related Kaposi's sarcoma. Proc.  Natl.  Acad.  Sci.  USA. 
91:5281-5285. 
Nakamura,  T.,  T.  Nishizawa,  M.  Hagiya,  T.  Scki,  M.  Shimonishi,  A. 
Sugimura, and S. Shimizu. 1989. Molecular cloning and expression of hu- 
man hepatocyte growth factor. Nature (Lond.).  342:440-443. 
Naldini,  L.,  E.  Vigna,  R.  Narsimhan,  G.  Guadino,  R.  Zarnegar,  G. 
Michalopoulos,  and  P.  M.  Comoglio.  1991.  Hepatocyte  growth factor 
(HGF) stimulates the tyrosine kinase activity of the receptor encoded by the 
proto-uncogene c-MET. Oncogene.  6:501-504. 
Rosen, E. M., I. D. Goidberg, B. M. Kacinski, T. Buckholz, and D. W. Vinter. 
1989.  Smooth muscle releases an epithelial  cell scatter factor which binds 
to beparin. In Vitro Cell Dev. Biol.  25:163-173. 
Rosen, E. M., L. Meromsky, E. Setter,  D. W. Vinter, and I. D. Goldberg. 
1990a.  Purification  and migration-stimulating activities of scatter factor. 
Proc. Soc. Exp.  Biol.  Med.  195:34-43. 
Rosen, E. M., L. Meromsky, E. Setter, D. W. Vinter, and I. D. Goldberg. 
1990b.  Smooth muscle-derived factor stimulates mobility of human tumor 
ceils. Invasion Metast.  10:49-64. 
Rosen, E. M., I. D. Goldberg, D. Liu, E. Setter,  M. A. Donovan, M. Bhar- 
gava, M. Reiss, and B. M. Kacinski. 1991. Tumor necrosis factor stimulates 
epithelial  tumor cell motility. Cancer Res. 57:5315-5321. 
Rosen, E. M., J. Knesel, I. D. Goldberg, M. Bhargava, A. Joseph, R. ZituLk, 
J. Wines, M. Kelley, and S. Rockwell. 1994.  Scatter factor modulates the 
metastatic phenotype of the EMT6 mouse mammary tumor. Int. J. Cancer. 
57:706-714. 
Rubin, J. S., A.  M.-L. Chart,  D. P. Bottaro, W. H. Burgess, W. G. Taylor, 
A. C. Cech, D. W. Hirschfield, J. Wong, T. Miki, P. W. Finch, and S. A. 
Aaronson. 1991. A broad spectrum hmnan lung fibroblast-derived mitogen 
is a  variant of hepatocyte growth factor.  Proc.  Natl.  Acad.  Sci.  USA. 
88:415--419. 
Seslar, S. P., T. Nakamura, and S. W. Byers. 1993. Regulation of fibroblast 
hepatocyte growth factor/scatter factor expression by human breast carci- 
noma cell lines and peptide growth factors. Cancer Res. 53:1233-1238. 
Sormenberg, E., D. Meyer, K. M. Weidner, and C. Birehraeier.  1993. Scatter 
factorhaepatocyte  growth factor and its receptor, the c-met tyrosine kinase, 
can mediate a signal exchange between between mesenchyme  and epithelia 
during mouse development. $.  Cell Biol.  123:223-235. 
Stampfer, M. R., R. C. Hallowes, and A. J. Hackett. 1980. Growth of normal 
human mammary cells in culture. In Vitro Cell Dev. Biol.  16:415--425. 
Stoker, M., and M. Perryman. 1985.  An epithelial  scatter factor released by 
embryo fibroblasts. J.  Cell Sci.  77:209-223. 
Stoker, M., E. Gherardi, M. Perryman, and J. Gray.  1987.  Scatter factor is 
a fibroblast-derived modulator of epithelial  cell mobility. Nature (Lond.). 
327:238-242. 
Tamura, M., N. Arakaki, H. Tsoubouchi, H. Takada, and Y. Daikuhara. 1993. 
Enhancement  of human  hepatocyte growth factor production by interleukin-  1 
alpha and -1 beta and tumor necrosis factor-alpha by fibroblasts in culture. 
J. Biol.  Chem.  268:8140-8145. 
Tsao, M. S., H. Zhu, A. Giaid, J. Viallet,  T. Nakamura, and M. Park. 1993. 
Hepatocyte growth factor/scatter factor is an autocrine factor for human 
bronchial  epithelial  and  lung  carcinoma  cells.  Cell  Growth  Differen. 
4:571-579. 
Tsarfaty, I., J. H. Resau, S. Rulong, I. Keydar, D. Faletto,  and G. F. Vande 
Woude.  1992.  The met proto-oncogene receptor  and  lumen formation. 
Science (Wash.  DC). 257:1258-1261. 
Tsubouchi, H., E. Gohda, A. J. Strain, and Y. Daikuhara. 1993.  The role of 
HGF-SF in animal and human  hepatic physiology and pathology. In Hepato- 
cyte Growth Factor-Scatter Factor and the c-Met Receptor. I. D. Goldberg, 
and E. M. Rosen, editors. Birkhauser-Verlag, Basel, 251-274. 
van den Hooff, A. 1988. Stromal involvement in malignant growth. Adv. Can- 
cer Res.  50:159-196. 
Weidner, K. M., J. Behrens, J. Vandekerckhove, and W. Birchmeier. 1990. 
Scatter factor: Molecular characteristics and effect on invasiveness  of epithe- 
lial cells. J.  Cell Biol.  111:2097-2108. 
Weidner, K. M., N. Arakaki, J. Vandekerckhove, S. Weingart, G. Hartmann, 
H. Rieder, C. Fonatsch, H. Tsubouchi, T. Hishida, Y. Daikuhara, and W. 
Birchmeier. 1991. Evidence for the identity of human scatter factor and hu- 
man hepatocyte growth factor. Proc. Natl. Acad. Sci.  USA. 88:7001-7005. 
Zarnegar, R., and G. Michalopoulos. 1989. Purification  and biologic character- 
ization  of human hepatopoietin  A, a polypeptide growth factor for hepato- 
cytes. Cancer Res. 49:3314-3320. 
The Journal of Cell Biology, Volume 127,  1994  234 